{"title":"Post-test medical diagnostic accuracy measures: an innovative approach based on the area under F-scores curves.","authors":"Hani Samawi, Jing Kersey, Marwan Alsharman","doi":"10.1080/10543406.2025.2512989","DOIUrl":null,"url":null,"abstract":"<p><p>Clinicians have increasingly turned to F-scores to gauge the accuracy of diagnostic tests. However, the dependency of F-scores on the prevalence of the underlying illness poses challenges, especially when prevalence varies across regions or populations, potentially leading to misdiagnoses. To address this issue, this article presents novel post-test diagnostic precision metrics for continuous tests or biomarkers. These metrics are based on the collective areas under the F-score curves across all conceivable prevalence values. Unlike traditional measures, the proposed metrics remain constant regardless of disease prevalence, enabling fair comparisons of different diagnostic tests and biomarkers' abilities in rule-in, rule-out, and overall accuracy. The article also explores the relationship between the proposed metrics and other diagnostic accuracy measures. Numerical illustrations and a real-world breast cancer dataset exemplify the application of the proposed metrics.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-18"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2512989","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Clinicians have increasingly turned to F-scores to gauge the accuracy of diagnostic tests. However, the dependency of F-scores on the prevalence of the underlying illness poses challenges, especially when prevalence varies across regions or populations, potentially leading to misdiagnoses. To address this issue, this article presents novel post-test diagnostic precision metrics for continuous tests or biomarkers. These metrics are based on the collective areas under the F-score curves across all conceivable prevalence values. Unlike traditional measures, the proposed metrics remain constant regardless of disease prevalence, enabling fair comparisons of different diagnostic tests and biomarkers' abilities in rule-in, rule-out, and overall accuracy. The article also explores the relationship between the proposed metrics and other diagnostic accuracy measures. Numerical illustrations and a real-world breast cancer dataset exemplify the application of the proposed metrics.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.